EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer



Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer



Cancer Research 54(1): 16-20



The HER-2/neu protooncogene is amplified and overexpressed in 20-40% of invasive breast cancers. HER-2/neu protein overexpression is associated with aggressive disease and is an independent predictor of poor prognosis in several subsets of patients. The protein may also be related to cancer formation, with overexpression being detectable in 50-60% of ductal carcinomas in situ. It has been suggested that it might be possible to develop specific T-cell therapy directed against proteins involved in malignant transformation. One question is whether normal proteins that are overexpressed are appropriate targets for therapeutic immune attack. This report demonstrates that some patients with HER-2/neu-positive breast cancers have both existent CD4+ helper/inducer T-cell immunity and antibody-mediated immunity to HER-2/neu protein. Initial studies performed on 20 premenopausal breast cancer patients identified antibodies to HER-2/neu in 11 individuals. Similar antibody responses have been found in some normal individuals. The patient with the greatest antibody response was studied in detail. In addition to a humoral immune response this patient had evidence of a significant proliferative T-cell response to the HER-2/neu protein and peptides. Similar T-cell responses have been detected in additional patients. It has been assumed that patients would be immunologically tolerant to HER-2/neu as a self-protein and that immunity might be difficult to generate. If immunity could be generated, the result might be destructive autoimmunity. The current data support the notion that HER-2/neu-specific immunity might be used in therapy without destroying normal tissue but also raises questions as to the role of existent immunity in immune surveillance and cancer progression.

(PDF 0-2 workdays service: $29.90)

Accession: 008650128

Download citation: RISBibTeXText

PMID: 7505195



Related references

Existent T cell and antibody immunity to HER-2/neu protein in breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 35(0): 498, 1994

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Research & Treatment 62(3): 245-252, August, 2000

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clinical Cancer Research 9(12): 4376-4386, 2003

Patients with breast or ovarian cancer have elevated T cell immunity to insulin-like growth factor binding protein 2 (IGFBP2). 2007

Vaccination with Dendritic Cell -Breast Cancer Fusions Induces Tumor Specific Immunity and Clinical Response in Patients with Metastatic Breast Cancer. Blood 100(11): Abstract No 2651, November 16, 2002

Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Human Immunology 60(6): 510-515, June, 1999

Reversible inhibitory activity of sera from breast cancer patients on estrogen effect on cell proliferation and protein synthesis of the human breast cancer cell line mcf 7. European Journal of Cancer & Clinical Oncology 24(10): 1647-1654, 1988

Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. International Journal of Cancer 105(2): 221-225, 2003

Cell-mediated immunity in breast cancer patients. Biomedicine & Pharmacotherapy. 50(8): 337-343, 1996

Cell mediated immunity in breast cancer patients. Onkologie 5(SPEC ISSUE): 42-45, 1982

Antibody dependent cell-mediated cytotoxicity in breast cancer patients in phase III clinical trials of a humanized anti-HER2 antibody. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 602, 1997

Cell mediated immunity in nonrelapsed breast cancer patients. Biomedicine & Pharmacotherapy 47(6-7): 291, 1993

Cell mediated immunity cm in non relapsed breast cancer patients. European Journal of Cancer 27(SUPPL 3): S19, 1991